Biochanin

Biochanin A: A Comprehensive Reference Article

1. Identity: Chemical and Botanical Profile

1.1 Chemical Identity

Biochanin A (systematically named 5,7-dihydroxy-4′-methoxyisoflavone) is a phytochemical phytoestrogen classified as an isoflavonoid. It is an O-methylated isoflavone and a natural organic compound in the class of phytochemicals known as flavonoids. Its formal IUPAC name is 5,7-dihydroxy-3-(4-methoxyphenyl)-4H-1-benzopyran-4-one, and it carries CAS number 491-80-5. Known synonyms include 4′-methyl genistein, 5,7-dihydroxy-4′-methoxyisoflavone, and NSC 123538. Its molecular formula is C₁₆H₁₂O₅.

Biochanin A is the methylated precursor of the isoflavone genistein (GEN), which is another well-studied isoflavone. The structural relationship is direct: also known as 4′-methyl genistein, biochanin A can be metabolized in vivo to genistein, another phytoestrogen with diverse effects.

1.2 Natural Sources

Biochanin A is the main isoflavone component of red clover (Trifolium pratense L.) and the commercially available extracts made of this plant. It is present in edible plants such as chickpeas, red clover, peanuts, soybean, alfalfa, and astragalus. Among these, the highest levels of BCA are found in red clover leaves, while lower levels are found in peanut, alfalfa, and other sources. In contrast to its unmethylated analogue genistein, biochanin A is not present in soy at significant quantities, but it can be found in many other legume plants and peanuts.

Nutritionally speaking, chickpeas are an essential source of biochanin A and a significant source of BCA intake for the general public. The role of biochanin A and other isoflavones in these plants is not known in detail, but generally speaking such secondary metabolites are produced to protect the plant from radiation and microbial attacks.

1.3 Common Forms and Preparations

Botanical dietary supplements derived from red clover are sold in tablet form in several countries. Formulations have also been explored as buccal (oromucosal) films, with research demonstrating permeation of biochanin A across porcine buccal mucosa without detectable metabolism. Traditional preparations include infusions, decoctions, and tinctures, each producing different chemical profiles. Biochanin A and formononetin are identified and quantified in all three preparation types. Both infusions and decoctions show higher concentrations of isoflavonoid glucosides than 45% ethanolic tinctures. Dynamic chemical variability of the red clover tincture was observed over time (one month), with biochanin A and formononetin reaching peak concentrations at around six days.

Various formulation approaches including enteric coating, solid dispersions, and lipid-based nanoparticles have evolved over time to improve the aqueous solubility and bioavailability of this phytoestrogen. Recent studies employing biochanin A–loaded nanoparticles have shown improved pharmacokinetics, including prolonged circulation time and enhanced tissue accumulation, particularly in tumor-bearing animal models.

2. Traditional and Historical Use

2.1 European Folk Medicine

Traditional Chinese Medicine and Western folk medicine used red clover (Trifolium pratense, the primary botanical source of biochanin A) as a diuretic, a cough expectorant (an agent that promotes discharge of mucus from the respiratory passages), and an alterative. Alterative plants were considered beneficial for chronic conditions, particularly those afflicting the skin. Red clover is known as an alterative agent — in other words, one that produces gradual beneficial changes in the body, usually by improving nutrition; also known as a "blood cleanser." It is a traditional remedy for psoriasis and eczema.

European herbalists documented its use for respiratory conditions, wound healing, and women's reproductive wellness as early as the 14th century. Red clover has long been regarded in European and folk herbal traditions as a "blood purifier" and lymphatic tonic. Herbalists used the blossoms as an alterative to support the body's natural detoxification processes, promote clearer skin, and ease stubborn, lingering congestion. The plant was also valued as a gentle expectorant to relieve coughs and bronchial irritation. Topically, poultices made from red clover were used to soothe rashes, eczema, and wounds.

2.2 North American Indigenous and Other Traditions

Red clover is a perennial flowering plant in the legume family that has served as both food and medicine across cultures for millennia. Indigenous peoples of North America used red clover as a spring tonic and blood purifier, while traditional Chinese medicine recognized it for clearing heat and supporting skin health.

Native American tribes used it as a dietary supplement and for skin conditions. European herbalists prescribed red clover preparations for respiratory ailments, while Russian folk medicine employed it for cancer treatment. Traditional Chinese Medicine incorporated red clover for detoxification and to support women's health during menopause.

2.3 Traditional Preparations

The principal plant parts employed medicinally were the blossoms. Red clover flowers have been used traditionally as a sedative, to purify the blood, and to treat respiratory conditions; topical preparations have been used for psoriasis, eczema, and rashes, and to accelerate wound healing. Infusions, decoctions, and tinctures were shown to produce different chemical profiles, meaning each traditional mode of preparation yielded a distinct phytochemical composition. Many of the chemical constituents present in red clover have been identified, including volatile oil, isoflavonoids, coumarin derivatives, and cyanogenic glycosides. Few scientific studies, however, have confirmed the folk use of red clover remedies.

2.4 Use in Women's Health

Biochanin A has been popular for ages among menopausal women in controlling symptoms. It is a chief phytoconstituent of the red clover plant, which is well known for alleviating menopause symptoms through its oestrogenic and antioxidant properties. Its current commercial status reflects this tradition: biochanin A is an isoflavone isolated from red clover (Trifolium pratense), and is a commercially available nutraceutical for women suffering from postmenopausal symptoms.

3. Key Constituents, Active Compounds, and Mechanisms of Action

3.1 Phytoestrogenic Activity

Isoflavones resemble the structure of oestrogen, and display agonistic and antagonistic interactions with the oestrogen receptor. BCA has a remarkably close structural resemblance with endogenous estrogen 17β-estradiol (E2) and has been reported to act via nuclear estrogen receptors (ERs, α and β) and membrane-bound ERs, such as G protein–coupled receptor 30 (GPR30, also known as G protein–linked estrogen receptor 1). GPR30 is a common target for isoflavones to promote rapid cellular signaling, and it is expressed in the central nervous system, skin, adipose tissue, and skeletal muscle, as well as in monocytes, eosinophils, and neutrophils.

BCA may act as a natural selective ER modulator that elicits distinct clinical effects from estrogens used for hormone replacement by selectively recruiting coregulatory proteins to ERβ to trigger transcriptional pathways. Isoflavones have 1000-fold weaker binding affinity than estradiol to ERα. Although the stronger binding affinity to ERβ of isoflavones is also lower than estradiol, isoflavones can circulate at concentrations of 10,000 times that of estrogen and thereby achieve greater binding potential through abundance.

3.2 Aromatase (CYP19) Inhibition and Steroid Enzyme Modulation

Overexposure to oestrogen is a major contributing factor in the development of breast cancer, and cytochrome P450 (CYP) 19 enzyme, or aromatase, catalyses the reaction converting androgen to oestrogen. By assaying MCF-7 cells stably transfected with CYP19, biochanin A inhibited aromatase activity and hampered cell growth. In addition, 25 µM biochanin A significantly reduced CYP19 mRNA abundance in the oestrogen receptor-negative breast cancer cells SK-BR-3. Since genistein is a major metabolite of biochanin A, it might contribute to biochanin A's suppressive effect on CYP19 expression.

Biochanin A can affect hormone levels by inhibiting 5α-reductase and 17β-hydroxysteroid dehydrogenase or altering aromatase (CYP19A1) activity.

3.3 Anti-inflammatory Mechanisms

Biochanin A is considered an anti-inflammatory agent with regards to its inhibitory effect in the release of nitric oxide (NO) production by LPS (lipopolysaccharide), IKK (IκB kinase) activity, and NF-κB activation, and lowered IL-6, IL-1β, and TNF-α production in RAW264.7 cells. It competes with the inflammation by impeding the release of pro-inflammatory cytokines and modulating NF-κB and MAPK pathways.

The anti-inflammatory effect of BCA is believed to work by modulating various targets to prevent/reduce the inflammatory process, such as the inhibition of NF-κB and MAPK through the upregulation of PPAR-γ. Through PPAR-γ activation, biochanin A displays an anti-inflammatory effect and hence can be considered as an agent in the therapeutic management of inflammatory cardiovascular disease.

3.4 Antioxidant Activity

Isoflavonoids including biochanin A have the ability to scavenge free radicals and reduce oxidative stress. The first line of antioxidant defence against reactive oxygen species is constituted by enzymes, like superoxide dismutase and catalase. Biochanin A prevents oxidative stress by elevating the levels of these antioxidant enzymes.

In neurological models, biochanin A treatment suppressed brain oxidative stress levels, promoted Nrf2 nuclear translocation, increased the expression of HO-1, and inhibited activation of the NF-κB pathway in ischemic brain tissues.

3.5 PPAR Signaling and Metabolic Regulation

Biochanin A intersects with signaling through peroxisome proliferator-activated receptors (PPARs), as it activates PPARγ (EC₅₀ = 19 µM) and has also been shown to activate a PPARα promoter. Moreover, it increases the expression of the PPARγ coactivator PGC-1α, promoting mitochondrial biogenesis.

3.6 Phosphodiesterase-4 (PDE4) Inhibition

In 2004, researchers reported that biochanin A selectively inhibited phosphodiesterase (PDE)4 activity. PDE4 inhibition is a recognized mechanism relevant to airway hyperresponsiveness and asthma, and this activity has been explored in animal models of allergic airway disease.

3.7 Fatty Acid Amide Hydrolase (FAAH) Inhibition

Biochanin A inhibits fatty acid amide hydrolase (FAAH) with an IC₅₀ of 2.4 µM and acts as an agonist of the aryl hydrocarbon receptor (EC₅₀ = 0.25 µM). The effect of biochanin A on fatty acid amide hydrolase inhibition was also studied in vivo in a formalin model of pain, and it was observed that biochanin A reduced the formalin-induced phosphorylation of spinal extracellular signal-regulated kinase and thus peripheral pain sensitization.

3.8 Apoptotic and Anticancer Pathways

The level of tyrosine kinase is interrupted and signal transduction is inhibited. Biochanin A induces ERβ and E-cadherin and inhibits cell proliferation. It inhibits NF-κB and induces TRAIL-associated apoptosis. It also increases conversion of testosterone into glucuronide, resulting in low appearance of prostate-specific antigen (PSA). Biochanin A induces dose-dependent apoptosis, as evidenced by caspase-7 activation and PARP1 cleavage.

4. Scientific Evidence by Area of Use

4.1 Menopausal Symptoms (Vasomotor Symptoms)

Evidence strength: Moderate clinical evidence from randomized controlled trials and meta-analyses, though effects are of modest magnitude and study heterogeneity is a limitation.

A meta-analysis of eight trials (ten comparisons) demonstrated a statistically significant reduction in the daily incidence of hot flushes in women receiving red clover compared to those receiving placebo: weighted mean difference −1.73 hot flushes per day, 95% CI −3.28 to −0.18; p = 0.0292. Analysis showed that differences were substantive in comparisons of postmenopausal women with ≥5 hot flushes per day, when the follow-up period was 12 weeks, with an isoflavone dose of ≥80 mg/day, and when the formulations contained a higher proportion of biochanin A. The meta-analysis showed a statistically moderate relationship with the reduction in the daily frequency of hot flushes; however, further well-designed studies are required to confirm the present findings and to finally determine the effects of red clover on the relief of flushing episodes.

A specific double-blind randomized controlled trial: A parallel, double-blind, randomized control trial of 62 peri-menopausal women aged 40–65, reporting ≥5 hot flushes/day and follicle stimulating hormone ≥35 IU/L, was conducted. Participants received either twice daily treatment with a bioavailable red clover extract (RCE), providing 34 mg/day isoflavones and probiotics, or a masked placebo formulation for 12 weeks. A significant decrease in 24-hour hot flush frequency (p < 0.01) and intensity (p < 0.05) was found when comparing change from baseline to 12 weeks of the RCE (−4.3 HF/24hr, CI −6.8 to −2.3) with placebo (0.79 HF/24hr, CI −1.56 to 3.15).

Several systematic reviews and meta-analyses have been conducted on clinical trials using red clover for the reduction of menopausal symptoms. Overall, these studies suggest a very small positive effect with uncertain clinical relevance. The activity of BCA has not been adequately evaluated in humans as a standalone compound, since most trials use mixed isoflavone extracts.

4.2 Bone Health and Osteoporosis

Evidence strength: Preliminary; preclinical data are supportive, but clinical data remain limited.

Preliminary evidence suggests that red clover isoflavones may help prevent or treat osteoporosis. As a promising alternative estrogen therapy, BCA might be used for the management of renal and cutaneous changes observed in postmenopausal women while preventing bone loss.

Preclinically, the preventive effect of BCA on bone loss was evaluated in the ovariectomized rat model of osteoporosis, the most commonly used model for the study of human postmenopausal osteoporosis. Plasma BCA concentrations lower than or equal to 10⁻⁶ M are attainable with a daily oral intake of 5–50 mg per kg of body weight in rats. The maximum plasma concentration of any isoflavone rarely exceeds 10⁻⁶ M following dietary intake.

4.3 Cardiovascular Effects

Evidence strength: Preliminary to moderate; small clinical studies with inconsistent results.

In a double-blind, placebo-controlled comparative study of eighty people (both men and women), a red clover extract modified to be rich in biochanin did reduce LDL (bad) cholesterol, while one enriched in formononetin did not. One very small double-blind study found hints that red clover isoflavones might slightly improve blood pressure in postmenopausal women with diabetes.

Arterial compliance, an index of the elasticity of large arteries, improved in a small, short-term study of postmenopausal women receiving red clover. These results were confirmed by a larger study of normotensive men and postmenopausal women. Ambulatory blood pressure remained unchanged, but total peripheral resistance improved in these patients. Participants received a supplement of red clover–derived isoflavone 80 mg/day containing mostly biochanin A or formononetin; improvements were greatest in the formononetin group.

In a small clinical trial (N = 23), red clover 86 mg/day isoflavone had no effect on homocysteine, while women receiving 40 to 80 mg daily of red clover isoflavones in another trial (N = 43) experienced decreased insulin sensitivity.

In animal models of cardiac injury: male Wistar rats were treated with three BCA doses (5, 10, and 20 mg/kg) in a streptozotocin and isoproterenol-induced model of diabetic myocardial infarction. BCA administration significantly improved electrocardiographic parameters by reducing ST height and QT interval prolongation (p < 0.05). It also reduced myocardial injury markers in a dose-dependent manner (p < 0.001). BCA normalized blood pressure, heart rate, and left ventricular function. These are animal data and do not demonstrate human efficacy.

4.4 Cancer Biology

Evidence strength: Preclinical only (in vitro and animal studies); no confirmed clinical evidence in humans.

Inspired by epidemiological evidence suggesting that a relationship exists between the consumption of certain foods containing isoflavones and decreased cancer incidence in humans, BCA has been evaluated in many studies related to cancer treatment. The first study was performed in 1988 in hamster embryo cell cultures and found that BCA inhibited carcinogen activation. Subsequently, studies investigating the anticancer activity of BCA were carried out in different cancer cell lines, followed by animal models.

Many types of tumors could be inhibited by BCA, such as lung cancer, prostate cancer, gastrointestinal tract cancer, pancreatic cancer, breast cancer, osteosarcoma, malignant melanoma, and tumors of the central nervous system. These findings are exclusively preclinical. There is no evidence that red clover can help treat cancer. However, its usage in many parts of the world as a traditional cancer remedy has prompted scientists to take a close look at the herb. It turns out that the isoflavones in red clover may possess antitumor activity in the test tube.

With regard to hormone-dependent cancers like breast, prostate, and other malignancies like pancreatic, colon, lung, osteosarcoma, and glioma that have limited treatment options, biochanin A revealed agreeable results in arresting cancer development — though these results are from cell and animal studies, not human trials.

4.5 Neuroprotection

Evidence strength: Preclinical only; promising in vitro and animal data but no human trials specifically for biochanin A.

Biochanin A has been shown to have a potential neuroprotective impact by modulating multiple critical neurological pathways. Isoflavone-enriched extracts have shown neuroprotective effects in human cortical neurons.

In a key preclinical study, biochanin A was shown to improve neurological effect and to reduce infarct volume and brain edema in cerebral ischemia/reperfusion rats. Biochanin A treatment suppressed brain oxidative stress levels, promoted Nrf2 nuclear translocation, increased the expression of HO-1, and inhibited activation of the NF-κB pathway in ischemic brain tissues. These findings suggest that biochanin A provides neuroprotection through regulation of oxidative stress and inflammation pathways.

In an Alzheimer's-related cell model, biochanin A was used as a potential alternative to estrogen replacement therapy via investigation of its neuroprotective effects against Aβ₂₅–₃₅-induced toxicity in PC12 cells. Exposure of cells to the Aβ₂₅–₃₅ protein significantly increased cell viability loss and apoptosis. However, the effects induced by Aβ₂₅–₃₅ were markedly reversed in the presence of biochanin A; pretreatment attenuated the cytotoxic effect by decreasing viability loss, LDH release, and caspase activity. These are in vitro data only.

Biochanin A protected dopaminergic neurons against lipopolysaccharide-induced damage by inhibiting microglial activation and proinflammatory factors.

4.6 Metabolic Disorders (Diabetes, Lipid Metabolism)

Evidence strength: Preclinical only; no adequately powered human trials specific to biochanin A.

In metabolic disorders, biochanin A acts by encouraging transcriptional initiation and inhibition, activating estrogen receptors, and increasing the activity of differentiation, autophagy, inflammation, and blood glucose metabolism. Biochanin A has also shown therapeutic benefits when administered for neurological disorders, diabetes, hyperlipidemia, and other chronic diseases/disorders — primarily in preclinical studies.

4.7 Airway Inflammation and Asthma

Evidence strength: Preclinical only.

Isoflavones inhibit the activity of aromatase (CYP19), thus decreasing estrogen biosynthesis. Biochanin A selectively inhibited phosphodiesterase (PDE)4 activity, a mechanism directly relevant to airway smooth muscle relaxation and the control of airway inflammation.

4.8 Anti-infective Properties

Evidence strength: In vitro only.

Isoflavones are naturally occurring phytoestrogens, antioxidants, and efflux pump inhibitors, but their therapeutic use is limited by poor water-solubility and intense first-pass metabolism. Biochanin A was the most potent Chlamydia growth inhibitor among the studied isoflavones, with an IC₅₀ = 12 µM on C. pneumoniae inclusion counts and 6.5 µM on infectious progeny production, both determined by immunofluorescent staining of infected epithelial cell cultures.

4.9 Cognitive Function

In a six-month, double-blind study, use of red clover isoflavones failed to enhance or harm mental function. This finding was from mixed isoflavone supplementation, not isolated biochanin A.

5. Body Systems and Health Areas Associated with Biochanin A

Biochanin A might be able to modify various systems of the human body like the cardiovascular system, CNS, respiratory system, etc. Biochanin A has been tested for its effect in various cancers, inflammation, osteoarthritis, metabolic disorders, cardiovascular diseases, antioxidant properties, hormone-dependent diseases, etc.

• Endocrine/Reproductive system: Phytoestrogenic activity at both ERα and ERβ, aromatase inhibition, and modulation of steroidogenesis in human granulosa cells.
• Musculoskeletal system: Potential bone-protective effects via modulation of osteoblasts and osteoclasts, primarily in preclinical models of postmenopausal osteoporosis.
• Cardiovascular system: Preliminary evidence for improvements in arterial compliance and LDL cholesterol in clinical studies; anti-inflammatory cardioprotective effects in animal models.
• Central nervous system: Preclinical neuroprotection via Nrf2/HO-1, NF-κB modulation, protection against Aβ toxicity, and protection of dopaminergic neurons.
• Respiratory system: Selective PDE4 inhibition, suppression of airway hyperresponsiveness in animal models.
• Metabolic system: PPAR-γ activation, mitochondrial biogenesis induction, glucose and lipid metabolism modulation.
• Oncology (preclinical): Antiproliferative, pro-apoptotic, and anti-invasive effects in multiple cancer cell lines; no confirmed clinical efficacy.

6. Pharmacokinetics and Bioavailability

Biochanin A is an isoflavone mainly found in red clover with poor solubility and oral absorption. Both BCA and genistein were found to have a high clearance and a large apparent volume of distribution; the bioavailability of both was poor (<4%). Reentry peaks were evident after oral administration of both BCA and GEN, suggesting enterohepatic cycling. The free fraction of BCA in rat plasma was 1.5%.

ADMET profile predictions suggest that biochanin A exhibits favorable permeability across Caco-2 and PAMPA membranes, whereas MDCK permeability is poor. Despite its predicted gastrointestinal absorption, the compound demonstrates poor oral bioavailability, particularly at thresholds above 30%. Biochanin A exhibits high plasma protein binding (97.16%) and a very low volume of distribution, indicating limited free drug availability and minimal tissue distribution.

The compound exhibits moderate plasma clearance (CLplasma = 5.446 mL/min/kg), while its predicted half-life (T½ = 0.858 h) is classified as ultra-short, indicating the need for frequent dosing.

Despite its huge potential, the clinical use of this isoflavone is limited due to its low bioavailability. Various strategies developed to enhance the bioavailability of biochanin A have led to the foresight that this promising molecule could increase health benefits in the future.

7. Dosage Forms and Reported Dosages

Red clover blossoms for sedation were formerly used at doses of 4 g, but are now used primarily as a source of isoflavones. The usual dose reported in the literature is 40 to 80 mg/day of standardized isoflavones, typically containing biochanin A, formononetin, genistein, and daidzein.

Some evidence suggests that 80 mg daily is a sufficient dosage to reduce menopausal hot flashes. The longest clinical trial to date investigating high-dose treatments (80 mg/day and 120 mg/day) for three years found no significant effects on adverse events or side effects compared to placebo.

In a specific clinical trial referenced above, participants received twice daily treatment with a bioavailable red clover extract (RCE), providing 34 mg/day isoflavones and probiotics, for 12 weeks.

In the preclinical cardioprotection study, male Wistar rats were treated with three BCA doses of 5, 10, and 20 mg/kg — these are animal doses and cannot be directly extrapolated to humans.

Numerous preclinical reports demonstrate the efficacy and safety of biochanin A. Though it has been used clinically for postmenopausal symptoms, more clinical studies are needed to be carried out further to evaluate it in terms of efficacy and safety for other therapeutic applications.

8. Safety Considerations and Drug Interactions

8.1 General Tolerability

Bioactive isoflavones from red clover, particularly biochanin A and formononetin, show promise as candidates for treatment of menopause symptoms, as recent clinical trials have demonstrated beneficial effects against menopausal vasomotor symptoms and show minimal side effects with treatment. The safety profile of these compounds is promising and tested in numerous human trials.

8.2 Cytochrome P450 Interactions

Metabolism predictions indicate that biochanin A is a strong inhibitor and substrate of multiple cytochrome P450 enzymes, including CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP2B6, and CYP2C8, reflecting a high likelihood of metabolic interactions. The human liver microsomal (HLM) stability value (0.388) suggests moderate metabolic stability. These are computational predictions and the clinical significance in humans requires further evaluation.

8.3 P-Glycoprotein (P-gp) Interactions

Biochanin A has been shown in vitro to inhibit P-glycoprotein, a key drug efflux transporter. However, the in vivo relevance appears limited: in contrast to the in vitro results, intraperitoneal or oral administration of biochanin A did not significantly change the pharmacokinetics of doxorubicin and cyclosporine A. Moderate interaction was observed between biochanin A and paclitaxel, resulting in lower AUC values. The disconnect between the in vitro and in vivo data suggests that P-gp interactions mediated by biochanin A may be limited due to its poor bioavailability and rapid clearance.

8.4 Tamoxifen Interaction

Reduced bioavailability of tamoxifen and its metabolite 4-hydroxytamoxifen after oral administration with biochanin A was reported in rats. These are animal pharmacokinetic data, and the clinical relevance in humans has not been confirmed.

8.5 Endocrine Disruption Concern

Biochanin A (BCA), an isoflavone with anti-inflammatory and estrogen-like properties, has been identified as an endocrine-disrupting chemical (EDC). Background: endocrine-disrupting chemicals interfere with the endocrine system and negatively impact reproductive health. Its weak binding to estrogen receptors suggests a reduced potential for endocrine disruption and a potentially safer profile for use in hormone-sensitive conditions.

8.6 Predicted Toxicological Signals

Computational toxicity predictions reveal a high risk of drug-induced liver injury (DILI), genotoxicity, carcinogenicity, respiratory toxicity, and eye irritation. Moderate risks were observed for AMES mutagenicity, skin sensitization, human hepatotoxicity, and HEK293 cytotoxicity. It is important to note that these are in silico predictions from an ADMET modeling tool, not confirmed clinical outcomes. Mutagenicity related to genistein use is not presented in biochanin A–associated studies.

8.7 Outstanding Research Needs

The safety and efficacy of biochanin A needs to be established in clinical trials involving human subjects. The current body of evidence is predominantly preclinical. Where clinical evidence exists, it generally uses mixed red clover isoflavone extracts rather than isolated biochanin A, limiting conclusions about the specific contribution of this compound.

References

• Le Bail JC et al. "The red clover (Trifolium pratense) isoflavone biochanin A inhibits aromatase activity and expression." Journal of Steroid Biochemistry and Molecular Biology (2007). PubMed PMID 17761019.
• Sarfraz I et al. "Biochanin-A: A Bioactive Natural Product with Versatile Therapeutic Perspectives." Current Pharmaceutical Design (2022). PubMed PMID 35579127.
• Surendraraj A et al. "Inhibitory Activity of the Isoflavone Biochanin A on Intracellular Bacteria of Genus Chlamydia and Initial Development of a Buccal Formulation." PMC4267780.
• Yan J et al. "Biochanin A from Chinese Medicine: An Isoflavone with Diverse Pharmacological Properties." American Journal of Chinese Medicine (2021). PubMed PMID 34530697.
• Booth NL et al. "Dynamics of the isoflavone metabolome of traditional preparations of Trifolium pratense L." PubMed PMID 30981705.
• Zhang Y et al. "Chemical and Biological Properties of Biochanin A and Its Pharmaceutical Applications." PMC10143291.
• Moon YJ et al. "Pharmacokinetics and bioavailability of the isoflavone biochanin A in rats." PMC2761049.
• Yalçın M et al. "Molecular Mechanisms of Biochanin A in AML Cells: Apoptosis Induction and Pathway-Specific Regulation in U937 and THP-1." PMC12154116.
• Anuranjana PV et al. "Mechanisms Behind the Pharmacological Application of Biochanin-A: A review." PMC10725524. F1000Research (2023).
• Wang H et al. "Biochanin A Provides Neuroprotection against Cerebral Ischemia/Reperfusion Injury by Nrf2-Mediated Inhibition of Oxidative Stress and Inflammation Signaling Pathway in Rats." PMC6896748.
• Huang WC et al. "Biochanin A, a Phytoestrogenic Isoflavone with Selective Inhibition of Phosphodiesterase 4, Suppresses Ovalbumin-Induced Airway Hyperresponsiveness." PMC3062156.
• Tavares LP et al. "Biochanin A Regulates Key Steps of Inflammation Resolution in a Model of Antigen-Induced Arthritis via GPR30/PKA-Dependent Mechanism." PMC8114065.
• Biochanin A exerts an anti-inflammatory effect on adipose tissue and liver of ovariectomized obese mice. PMC12622944.
• Yu C et al. "Perspectives Regarding the Role of Biochanin A in Humans." Frontiers in Pharmacology 10:793 (2019). PMC6639423.
• Sun XX et al. "The Preventive Effect of Biochanin A on Bone Loss in Ovariectomized Rats: Involvement in Regulation of Growth and Activity of Osteoblasts and Osteoclasts." PMC3594937.
• Xiao X et al. "Neuroprotective Effects of Biochanin A against β-Amyloid–Induced Neurotoxicity in PC12 Cells via a Mitochondrial-Dependent Apoptosis Pathway." PMC6274559.
• Mahajan UB, Goyal S. "Biochanin A Mitigates Oxidative Stress and Inflammation in Diabetic Myocardial Infarction." Cureus (2025). PMC12038873.
• Kanadys W et al. "Evaluation of Clinical Meaningfulness of Red Clover (Trifolium pratense L.) Extract to Relieve Hot Flushes and Menopausal Symptoms in Peri- and Post-Menopausal Women: A Systematic Review and Meta-Analysis of Randomized Controlled Trials." PMC8069620.
• Thorup AC et al. "Combined Red Clover isoflavones and probiotics potently reduce menopausal vasomotor symptoms." PLOS ONE (2015). PMC5462345.
• EBSCO Research Starters: Red Clover's Therapeutic Uses. Complementary and Alternative Medicine.
• PeaceHealth Health Information Library: Red Clover.
• Memorial Sloan Kettering Cancer Center Integrative Medicine: Red Clover.
• Zhang S et al. "Interactions between the flavonoid biochanin A and P-glycoprotein substrates in rats: in vitro and in vivo." PubMed PMID 19499569.
• Srinivas NR. "Biochanin A: Understanding the Complexities in the Paradoxical Drug–Drug Interaction Potential." European Journal of Drug Metabolism and Pharmacokinetics (2015).
• Drugs.com Natural Product Database: Red Clover (Trifolium pratense).
• Luongo FP et al. "Biochanin A modulates steroidogenesis and cellular metabolism in human granulosa cells through TAS2Rs activation." PubMed PMID 39863886.